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Delayed hypersensitivity is one of several immune responses initiated by thymus-derived (T)
lyrriphocytes. Other functions of T cells are listed
in Table . 1 and summarized in reference 1. The
mononuclear infiltrate of delayed hypersensitivity is
a collaborative phenomenon between T lymphocytes
and monocytes. This collaboration can be separated
into components which I have chosen t6 call the
"three R's'~ of delayed hypersensitivity. In this discussion I will define these "three R's" and examine
the usefulness of this concept in clinical medicine.
Hematoxylin and eosin sections of skin biopsied
48 hours after intradermal injections of antigen
characteristically show mononuclear cells around
blood vessels and in connective tissue. As early as
1951, however, Gell and Hinde (2) reported that
the monocyte was the principal participant in the
skin site. In 1963, McCluskey (3), using radioisotopic techniques, found that 90% of the mononuclear cells in the reaction site were blood-borne
and originated from cells that had divided 48 hours
previously. Subsequently, cell transfer studies have
provided conclusive evidence that the rapidly dividing cells originated in the bone marrow and were
precursors of the blood monocyte. Tiie evidence is
as follows: 1) Injection of immune lymphocytes into
nonimmune, irradiated recipients failed to transfer
positive skin reactions ( 4); 2) Injection of bone
marrow cells from nonimmune donors to sensitized,
irradiated animals resulted in positive responses ( 5);
3) Local injection of nonimmune macrophages into
the skin of irradiated, sensitized recipients elicited
positive responses in these areas ( 6).
These studies indicated that two populations of
cells are required to elicit delayed hypersensitivity.

* Presented by Dr. Horwitz at the 45th Annual
McGuire Lecture Series, November 8, 1973, at the Medical
College of Virginia, Richmond.
MCV QUARTERLY 10(2) : 61 ·64. 1974

The first are radioresistant, which were later defined
as long-lived, T lymphocytes. The second population
are cells of the monocyte/ macrophage system and
are derived from radiosensitive precursors in the
bone marrow.
From this information we can develop a concept of delayed hypersensitivity consisting of three
components (Table 2). First, sensitized T lympho~
cytes, perhaps with some help from macrophages,
recognize intradermally injected antigen. Secondly,
antigenic contact triggers a response in sensitized
lymphocytes. Within a few hours these cells release
soluble mediators (7) called Iymphokines into the
environment and later, activated small lyrriphocytes
transform into blasts and proliferate. Thirdly, through
the amplifying effects of lymphokines, such as migration inhibitory factor (MIF) and monocyte chemotactic factor (MCF), other leukocytes, predominantly
monocytes, accumulate at the skin .test site and
comprise the reaction of delayed hypersensitivity.
This mononuclear infiltrate is similar to that of any
other chronic inflammatory reaction. The triggering
event, however, is an immunologically specific response of T lymphocytes.
Techniques are available to evaluate each of the
"three R's." The number of circulating T cells available for antigen recognition can be quantitated by
several methods. The most widely used method at
this time is a rosette technique. When sheep erythrocytes are incubated with human lymphocytes at 4 °C,
the erythrocytes form rosettes around T cells ( 8).
Secondly, heterologous anti-T lymphocyte serum has
been developed (9) and may be used to quantitate
T cells either by immunofluorescence or cytotoxicity.
The second component, response to antigen,
can be evaluated by measuring the lymphocyte pro~
Iiferative response to antigen. In these studies
lymphocytes are cultured with test antigen for five61
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TABLE 1
THYMUS-DERIVED LYMPHOCYTE FUNCTIONS

1.
2.
3.
4.

Delayed hypersensitivity
Activation of macrophages to resist infection
Rejection of allografts and tumors
Regulation of antibody production by B cells

to-seven days and proliferation is assayed by measuring incorporation of a radiolabeled DNA precursor.
Alternatively, one can measure lymphokine
production from antigenically stimulated lymphocytes. Migration inhibitory factor has received the
most attention (7). Various techniques to measure
MIF have been developed which are based on the
inhibition of leukocyte migration by the culture
supernatants of stimulated lymphocytes. The method
of Rocklin and David (10) correlates well with
delayed hypersensitivity. These workers use guinea
pig peritoneal macrophages as effector cells. Other
workers have substituted human "buffy coat" leukocytes for guinea pig macrophages ( 11 ) . Results
obtained with these cells as the indicator cells, however, did not always correlate with cutaneous skin
reactivity to antigen (12).
I prefer to measure MCF rather than MIF,
because both response and reaction can be evaluated.
With this technique we can detect mediator production from a given patient's lymphocytes and also
evaluate the capacity of that subject's monocytes to
respond to bis own mediator. With a method to

measure leukocyte chemotaxis, we can evaluate both
lymphocyte and monocyte function.
To perform this technique a chamber is divided
into an upper and lower compartment by Nuclepore®
membrane. Monocytes are placed in the upper chamber and the chemotactic stimulants in the lower
chamber. The specific migration of cells from the
upper to the lower surface of the membrane filter
is quantitated ( 13).
These in vitro methods can be used to define
the component that is defective in patients with
impaired delayed hypersensitivity. Lymphocytes from
children with a congenitally absent thymus gland
(the DiGeorge syndrome and Nezelof syndrome)
fail to form rosettes with sheep erythrocytes or to
proliferate in response to mitogens. These children,
then, do not have sufficient T lymphocytes capable
of antigenic recognition.
Impaired cell-mediated immunity in chronic
mucocutaneous candidiasis may be due to several
defects, either .in a response or reaction. Patients
with this disease usually have adequate numbers of
circulating lymphocytes but may have selective defects in lymphocyte or monocyte function. In some
subjects, blast transformation is intact but MIF is
absent ( 14). In others, mediator production is intact,
but these patients' lymphocytes fail to proliferate in
response to antigen (15). Finally, Snyderman (16)
reported a patient with chronic mucocutaneous candidiasis whose monocytes responded poorly to a
chemotactic stimulus. Although it is tempting to
speculate that the defects detected with in vitro

TABLE2
DELAYED HYPERSENSITIVITY
A COLLABORATIVE PARTICIPATION OF LYMPHOCYTES AND MACROPHAGES
IN AN IMMUNOLOGICALLY SPECIFIC INFLAMMATORY REACTION
Component
Assay System

1. The recognition by small (thymus-derived)
Quantitation of T lymphocytes by:
1. Spontaneous rosettes without sheep erythrocytes.
lymphocytes of material which is antigenic to the host.
2. lmmunofluorescence or cytotoxicity using heterologous
antihuman thymocyte serum.
2. A response of sensitized lymphocytes as detected by the
release of soluble factors (lymphokines) and later by
cell division.

Generation of lymphokines
1. Migration inhibitory factor (MIF)
2. Macrophage chemotactic factor (MCF)
Blast transformation and proliferation

3. A mononuclear inflammatory reaction, consisting
predominantly of "activated" macrophages, which
leads to the attack, destruction, and sequestration of
autologous or foreign materials.

Monocyte response to MCF
"Skin-window" assay
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techniques accurately reflect an in vivo disturbance,
the data must be interpreted with appropriate caution
at this time.
Delayed hypersensitivity may be impaired in
conditions without a demonstrable defect in cellular
function . Serum factors inhibit lymphocyte function
in certain diseases and several examples are listed
in Table 3. The role of these serum inhibitors has
not been defined. Moreover, primary disorders of
lymphocyte function have not been differentiated
from secondary effects caused by serum factor in
many diseases with impaired cellular immunity.
Recent studies from this laboratory suggest that
anergy in such diverse diseases as systemic lupus
erythematosus (SLE) and primary intracranial tumors ( 17) is caused by serum inhibitors rather than
defective cells. Fractionation of inhibitory serum
in patients with each of these diseases revealed an
IgG factor that broadly suppresses reactivity of
allogeneic as well as autologous lymphocytes. This
inhibitory lgG factor has been named lymphocyte
regulatory immunoglobulin (LRG) and increased
LRG in SLE may, in part, explain decreased delayed
hypersensitivity. Patients with SLE and other diseases also have a lymphocytotoxic antibody that
may depress cell function.
In summary, I have attempted to develop a
working model of delayed hypersensitivity that may
be useful in understanding areas puzzling to the nonimmunologist. The reader is urged to ask the following questions in order to evaluate scientific papers
dealing with defective cellular immunity in various
diseases. First, did the patients studied have adequate
numbers of circulating lymphocytes and monocytes?
Secondly, did the methods used evaluate a single
component of delayed hypersensitivity or were several components analyzed? Finally, did the authors
distinguish a primary cellular defect from secondary

TABLE 3
DISEASES WITH SERUM INHIBITORS OF LYMPHOCYTE FUNCTION
1.
2.
3.
4.
5.
6.
7.
8.
9.

Hematologic and solid tumors
Systemic lupus erythematosus
Tuberculosis
Multiple sclerosis
Hepatitis
Lepromatous leprosy
Ataxia telangiectasia
Multiparous women
Multiple transfusions
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humoral effects? Separation of delayed hypersensitivity into "three R's" may be helpful in organizing
and understanding present information.
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